Inhibrx draws $100M as Oxford Finance expands debt facility to $500M
What's the deal? Inhibrx (Nasdaq: INBX), a San Diego clinical-stage biopharmaceutical company, has drawn $100 million in new debt after amending its loan agreement with Oxford FinanceDealroom has a profile for this one. Try Dealroom →. The amendment expands the total credit facility to $500 million.
The details: The $100 million Term C Loan was funded on signing, part of an additional tranche of up to $325 million. A further $225 million — the Term D Loan — may be drawn in increments of $50 million or more, at the lenders' discretion. Inhibrx had previously drawn $175 million under the facility.
Inhibrx also issued Oxford warrants to buy 21,457 shares at a strike price of $93.21, equal to 2% of the Term C Loan value. The warrants are immediately exercisable and expire in 10 years.
What's the endgame? The company is developing two candidates, ozekibart (INBRX-109) and INBRX-106, both using multivalent protein-engineering formats. Chief financial officer Kelly Deck said the capital "allows us to maintain full momentum on the advancement of both programs as we await key upcoming data readouts."
Why now? Inhibrx Biosciences was spun out as a standalone company in 2024, after Inhibrx, Inc. sold itself and its INBRX-101 program to Sanofi. The debt line gives the young company runway to fund clinical work without diluting shareholders through an equity raise.
What could go wrong? The extra $225 million is not guaranteed — it sits at the lenders' sole discretion. Clinical-stage biotechs also carry binary risk: the debt hinges on trial data that has yet to read out.
The signal: Venture debt remains a favoured tool for biotechs looking to stretch runway between milestones. Oxford's willingness to expand the facility signals continued lender appetite for companies with pipelines nearing key catalysts.
Read more: morningstar.com
Image credit: Enzymlogic